Education
About Us
Working with TipRanks
Follow Us
Arrowhead Pharmaceuticals (ARWR)
NASDAQ:ARWR
ARWR Stock Chart & Stats
Day’s Range― - ―
52-Week Range$9.57 - $27.34
Previous CloseN/A
Volume680.40K
Average Volume (3M)2.39M
Market Cap
$2.95B
Enterprise Value$2.01B
Total Cash (Recent Filing)$900.37M
Total Debt (Recent Filing)$112.70M
Price to Earnings (P/E)―
Beta2.32
Next Earnings
Dec 01, 2025EPS Estimate
-0.17Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.26
Shares Outstanding138,257,550
10 Day Avg. Volume2,980,751
30 Day Avg. Volume2,392,407
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.68
Enterprise Value/Revenue3.36
Enterprise Value/Gross Profit3.48
Enterprise Value/Ebitda-28.85
Forecast
1Y Price Target
$35.44Price Target Upside67.33% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering11
Bulls Say, Bears Say
Bulls Say
Commercial LaunchThe commercial launch potential of plozasiran is reinforced by full enrollment across three global Phase 3 severe hypertriglyceridemia (sHTG) trials completed ahead of schedule.
Market AccessMarket access efforts have already reached payers representing over 85% of U.S. covered lives, with encouraging feedback suggesting likely coverage for patients.
Milestone PaymentARWR announced receipt of a $100mm milestone payment from SRPT, triggered by completion of one of two pre-specified enrollment targets and dose-escalation authorization in the Ph1/2 of ARO-DM1 for DM1.
Bears Say
Market CompetitionSHTG is a substantially larger market opportunity compared to FCS, which indicates a significant potential for growth.
Price TargetThe price target for ARWR has been reduced to $21 from $22.
Share SaleSRPT sold its remaining ARWR shares in a separate negotiated block trade, with all future milestone payments still payable in cash.
Arrowhead Pharmaceuticals News
ARWR FAQ
What was Arrowhead Pharmaceuticals’s price range in the past 12 months?
Arrowhead Pharmaceuticals lowest stock price was $9.57 and its highest was $27.34 in the past 12 months.
What is Arrowhead Pharmaceuticals’s market cap?
Arrowhead Pharmaceuticals’s market cap is $2.95B.
When is Arrowhead Pharmaceuticals’s upcoming earnings report date?
Arrowhead Pharmaceuticals’s upcoming earnings report date is Dec 01, 2025 which is in 95 days.
How were Arrowhead Pharmaceuticals’s earnings last quarter?
Arrowhead Pharmaceuticals released its earnings results on Aug 07, 2025. The company reported -$1.26 earnings per share for the quarter, missing the consensus estimate of -$0.952 by -$0.308.
Is Arrowhead Pharmaceuticals overvalued?
According to Wall Street analysts Arrowhead Pharmaceuticals’s price is currently Undervalued.
Does Arrowhead Pharmaceuticals pay dividends?
Arrowhead Pharmaceuticals does not currently pay dividends.
What is Arrowhead Pharmaceuticals’s EPS estimate?
Arrowhead Pharmaceuticals’s EPS estimate is -0.17.
How many shares outstanding does Arrowhead Pharmaceuticals have?
Arrowhead Pharmaceuticals has 138,257,550 shares outstanding.
What happened to Arrowhead Pharmaceuticals’s price movement after its last earnings report?
Arrowhead Pharmaceuticals reported an EPS of -$1.26 in its last earnings report, missing expectations of -$0.952. Following the earnings report the stock price went up 2.242%.
Which hedge fund is a major shareholder of Arrowhead Pharmaceuticals?
Currently, no hedge funds are holding shares in ARWR
Arrowhead Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$35.44 (67.33% Upside)
$35.44 (67.33% Upside)
Blogger Sentiment
Bullish
ARWR Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 1.1M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 2.6%
Last 30 Days ▲ 7.5%
Last 30 Days ▲ 7.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-16.42%
12-Months-Change
Fundamentals
Return on Equity
-34.80%
Trailing 12-Months
Asset Growth
56.22%
Trailing 12-Months
Company Description
Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in phase 2b and one phase 3 clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in Phase 2b clinical trial to reduce production of angiopoietin-like protein 3; ARO-HSD, which is in Phase 1/2a clinical trial to treat liver diseases; ARO-ENaC, which is in a Phase 1/2a clinical trial to reduce production of the epithelial sodium channel alpha subunit in the airways of the lung; ARO-C3 for the treatment of complement-mediated disease that is in Phase 1/2a clinical trial; ARO-Lung2 for the treatment of chronic obstructive pulmonary disorder; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-XDH to treat uncontrolled gout; ARO-COV for the treatment of COVID-19 and other pulmonary-borne pathogens; and ARO-HIF2, which is in phase 1b clinical trial to treat clear cell renal cell carcinoma. It is also involved in the development of JNJ-3989, a subcutaneously administered RNAi therapeutic candidate to treat chronic hepatitis B virus infection; Olpasiran to reduce the production of apolipoprotein A; and ARO-AMG1 for treating genetically validated cardiovascular targets. Arrowhead Pharmaceuticals, Inc. has a license and research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop ARO-JNJ1, ARO-JNJ2, and ARO-JNJ3 RNAi therapeutics for liver-expressed targets; and license and research collaboration agreement with Takeda Pharmaceuticals U.S.A., Inc. to develop RNAi therapeutic candidate as a treatment for liver disease. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California.
ARWR Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
Arrowhead Pharmaceuticals has made significant progress in its clinical pipeline and strategic partnerships, with several promising developments, such as the full enrollment of key studies and a substantial deal with Sanofi. However, the negative impact of Sarepta's restructuring on Arrowhead's stock price and increased operating expenses are notable concerns. The overall sentiment is cautiously optimistic, given the strong financial position and upcoming milestones.View all ARWR earnings summariesARWR Stock 12 Month Forecast
Average Price Target
$35.44
▲(67.33% Upside)
Technical Analysis
Agios Pharma
―
Beam Therapeutics
―
Disc Medicine
―
Kymera Therapeutics
―
Immunocore Holdings
―
Ownership Overview
4.14% Insiders
16.29% Mutual Funds
20.13% Other Institutional Investors
33.53% Public Companies and
Individual Investors